Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

What is next, and who is running it?

The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Include Phase 1
ClassNone selected

14 of 17 programs on this timeline

202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today

anti-PD-L1 (with imatinib) 1

Registry, Oct 2027

anti-PD-L1 (with regorafenib) 1

Registry, Jul 30, 2027

Class not reported 1

DCC-3009Phase 1/2
Registry, May 2028

HIF-2 alpha inhibitor 1

BelzutifanPhase 2
Registry, Nov 18, 2032

KIT type I TKI plus type II TKI combination 1

FDA PDUFA target action date (GIST, with sunitinib), Nov 30, 2026

KIT/PDGFRA TKI (type II) 1

ImatinibApproved
No dated milestone in 2025 to 2030

KIT/PDGFRA type I TKI 1

AvapritinibApproved
No dated milestone in 2025 to 2030

multi-kinase TKI 2

RegorafenibApproved
No dated milestone in 2025 to 2030
Registry, Mar 31, 2027

multi-kinase TKI (type II) 1

SunitinibApproved
No dated milestone in 2025 to 2030

selective KIT TKI 2

Registry, Mar 10, 2027
NB003Phase 2/3
Registry, Aug 2028

switch-control KIT/PDGFRA TKI 1

RipretinibApproved
Registry, Dec 2027

VEGFR2 TKI (with paclitaxel) 1

Registry, Aug 31, 2027